Pharmacogenomics in type 2 diabetes management: towards personalized medicine
- PDF / 83,956 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 22 Downloads / 192 Views
MEETING ABSTRACT
Open Access
Pharmacogenomics in type 2 diabetes management: towards personalized medicine Cheng Hu From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) Shanghai, China. 27-29 June 2012
There is inter-individual variability in the responses to anti-diabetic treatments, partly due to genetic factors involved in drug absorption, distribution, metabolism and target. The identification of genetic markers related to drug reaction can help physicians with the decisions of drug selection, dose titration, treatment duration, and avoidance of advert drug reactions. We focused on the effects of susceptibility genes for T2D on anti-diabetic drugs’ efficacy. With respect to repaglinide, genetic variants at multiple loci such as CYP2C8, SLCO1B1, KCNJ11, TCF7L2 and SLC30A8, affect either its pharmacokinetics or pharmacodynamics. We also made some efforts on pharmacogenetic studies of repaglinide efficacy. We recruited a total of 104 Chinese patients with type 2 diabetes and with no history of prior antidiabetic medications, to whom subsequent repaglinide monotherapy with a 48-week follow-up was applied. Based on studies on this cohort, genetic variations at KCNJ11, ABCC8, NOS1AP and KCNQ1 were found to be associated with repaglinide efficacy. Moreover, we also focused on investigations into possible genetic factors for rosiglitazone efficacy, and have already suggested effects of ABCA1 and SLC30A8 variants on the response to rosiglitazone treatment. In spite of all these advances in the field of pharmacogenetics of type 2 diabetes, the pace of clinical application of these findings is rather slow. Consequently, more researches especially randomized clinical trials into the practical utility should be conducted.
doi:10.1186/1479-5876-10-S2-A19 Cite this article as: Hu: Pharmacogenomics in type 2 diabetes management: towards personalized medicine. Journal of Translational Medicine 2012 10(Suppl 2):A19.
Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review
Published: 17 October 2012
• No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar
Correspondence: [email protected] Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory for Diabetes, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
• Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit
© 2012 Hu; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Data Loading...
